Therapeutic Advances in Musculoskeletal Disease (Apr 2024)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials

  • Angelo Fassio,
  • Davide Gatti,
  • Annalisa Biffi,
  • Raffaella Ronco,
  • Gloria Porcu,
  • Giovanni Adami,
  • Rosaria Alvaro,
  • Riccardo Bogini,
  • Achille P. Caputi,
  • Luisella Cianferotti,
  • Bruno Frediani,
  • Stefano Gonnelli,
  • Giovanni Iolascon,
  • Andrea Lenzi,
  • Salvatore Leone,
  • Raffaella Michieli,
  • Silvia Migliaccio,
  • Tiziana Nicoletti,
  • Marco Paoletta,
  • Annalisa Pennini,
  • Eleonora Piccirilli,
  • Maurizio Rossini,
  • Maria Luisa Brandi,
  • Giovanni Corrao,
  • Umberto Tarantino

DOI
https://doi.org/10.1177/1759720X241234584
Journal volume & issue
Vol. 16

Abstract

Read online

Background: Subjects with a fragility fracture have an increased risk of a new fracture and should receive effective strategies to prevent new events. The medium-term to long-term strategy should be scheduled by considering the mechanisms of action in therapy and the estimated fracture risk. Objective: A systematic review was conducted to evaluate the sequential strategy in patients with or at risk of a fragility fracture in the context of the development of the Italian Guidelines. Design: Systematic review and meta-analysis. Data sources and methods: PubMed, Embase, and the Cochrane Library were investigated up to February 2021 to update the search of a recent systematic review. Randomized clinical trials (RCTs) that analyzed the sequential therapy of antiresorptive, anabolic treatment, or placebo in patients with or at risk of a fragility fracture were eligible. Three authors independently extracted data and appraised the risk of bias in the included studies. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Effect sizes were pooled in a meta-analysis using fixed-effects models. The primary outcome was the risk of refracture, while the secondary outcome was the bone mineral density (BMD) change. Results: In all, 17 RCTs, ranging from low to high quality, met our inclusion criteria. A significantly reduced risk of fracture was detected at (i) 12 or 24 months after the switch from romosozumab to denosumab versus placebo to denosumab; (ii) 30 months from teriparatide to bisphosphonates versus placebo to bisphosphonates; and (iii) 12 months from romosozumab to alendronate versus the only alendronate therapy (specifically for vertebral fractures). In general, at 2 years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. Conclusion: The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or ‘bone builders’ in patients with very high or imminent risk of fracture.